Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab
Authors:
- Júlia Granell-GeliJGJúlia Granell-Geli
- Cristina Izquierdo-GraciaCICristina Izquierdo-Gracia
- Ares Sellés-RiusASAres Sellés-Rius
- Aina Teniente-SerraATAina Teniente-Serra
- Silvia Presas-RodríguezSPSilvia Presas-Rodríguez
- María José MansillaMMMaría José Mansilla
- Luis BrievaLBLuis Brieva
- Javier SotocaJSJavier Sotoca
- María Alba Mañé-MartínezMMMaría Alba Mañé-Martínez
- Ester MoralEMEster Moral
- Irene BragadoIBIrene Bragado
- Susan GoelzSGSusan Goelz
Open Access
- 10 December 2021
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (12) , 1347
Abstract
Natalizumab is a monoclonal antibody that binds CD49d. Although it is one of the most effective treatments for Relapsing-Remitting Multiple Sclerosis (RRMS), a dosing regimen has not been optimized for safety and efficacy in individual patients. We aimed to identify biomarkers to monitor Natalizumab treatment and to establish a personalized dose utilizing an ongoing longitudinal study in 29 RRMS patients under Natalizumab with standard interval dose (SD) of 300 mg/4wks or extended interval dose (EID) of 300 mg/6wks. Blood samples were analyzed by flow cytometry to determine CD49d saturation and expression in several T and B lymphocytes subpopulations. Each patient was analyzed at two different timepoints separated by 3 Natalizumab administrations. Natalizumab and sVCAM-1 levels in serum were also analyzed using ELISA. To determine the reproducibility of various markers, two different timepoints were compared and no significant differences were observed for CD49d expression nor for saturation; SD patients had higher saturation levels (~80%) than EID patients (~60%). A positive correlation exists between CD49d saturation and Natalizumab serum levels. CD49d expression and saturation are stable parameters that could be used as biomarkers in the immunomonitoring of Natalizumab treatment. Moreover, Natalizumab and sVCAM-1 serum levels could be used to optimize an individual’s dosing schedule.Keywords
Funding Information
- Instituto de Salud Carlos III (CD19/00209)
- Biogen Idec (001)
This publication has 34 references indexed in Scilit:
- Anti-Integrin Therapy for Multiple SclerosisAutoimmune Diseases, 2012
- JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patientsJournal of Translational Medicine, 2012
- Molecular Biology, Epidemiology, and Pathogenesis of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced Demyelinating Disease of the Human BrainClinical Microbiology Reviews, 2012
- Natalizumab (Tysabri)American Journal of Neuroradiology, 2010
- Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigmCell, 1994
- Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversityCell, 1991
- Signaling by vascular cell adhesion molecule‐1 (VCAM‐1) through VLA‐4 promotes CD3‐dependent T cell proliferationEuropean Journal of Immunology, 1991
- β1 Integrin‐mediated lymphocyte adherence to extracellular matrix is enhanced by phorbol ester treatmentEuropean Journal of Immunology, 1991
- T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1Nature, 1989
- The persistence of papovavirus BK DNA sequences in normal human renal tissueJournal of Medical Virology, 1981